-
Turkey arrests 110 coal miners on hunger strike
-
Associated British Foods to spin off Primark clothes brand
-
Pope visits Eq. Guinea on last stop of Africa tour
-
Hello Kitty's parent company to make own video games
-
Di Matteo says 'vital' for faltering Chelsea to add experience
-
Ex-Spurs star Davids condemns 'lack of quality, lack of management'
-
Turkmenistan, the gas giant increasingly dependent on China
-
Romanian AI music sensation Lolita sparks racism debate
-
Timberwolves battle back to stun Nuggets in NBA playoffs
-
Eta appointment 'no surprise' for Union Berlin's ascendant women
-
Democrats eye Virginia gains in war with Trump over US voting map
-
Tourists trickle back to Kashmir, one year after deadly attack
-
Inside the world of ultra-luxury wedding cakes
-
Chinese AI circuit board maker soars on Hong Kong debut
-
Oil prices dip, most stocks rise on lingering Iran peace hopes
-
Tim Cook's time as Apple chief marked by profit absent awe
-
Mitchell, Harden shine as Cavs down Raptors for 2-0 series lead
-
El Salvador's missing thousands buried by official indifference
-
Trump's Fed chair pick to face lawmakers at key confirmation hearing
-
PGA Tour to scrap Hawaii opening events from 2027
-
Amazon invests another $5 bn in Anthropic
-
Israel PM vows 'harsh action' against soldier vandalising Jesus statue in Lebanon
-
Wembanyama wins NBA defensive player of the year
-
'The Devil Wears Prada 2' stars reunite for glamorous premiere
-
El Salvador holds mass trial of nearly 500 alleged gang members
-
Apple's Tim Cook to step down as CEO in September
-
West Ham's draw at Palace relegates Wolves, piles pressure on Spurs
-
Canadian tourist killed in Mexico archaeological site shooting
-
Wolves relegated from Premier League
-
Oil jumps on Hormuz tensions, stocks mostly retreat
-
Colombian environmental activist honored amid threats and exile
-
Gun battle traps more than 200 tourists at Rio viewpoint
-
Alcaraz may skip French Open rather than rush injury comeback
-
Top US court to hear case of Catholic schools excluded from state funding
-
Trump Fed chair pick to vow interest rate independence at key hearing
-
EU to host Taliban officials for talks on deporting Afghans
-
Blue Origin probing rocket's failure to deliver satellite
-
Wembanyama 'changing the game as we speak', says Nowitzki
-
Swiss football club turn down Kanye West concert approach
-
Leicester fairytale turns sour as relegation to third tier looms
-
Pope Leo blasts 'exploitation' as he wrap up tour of resource-rich Angola
-
Varma ton revives Mumbai's IPL hopes with win over Gujarat
-
Formula One makes rule changes after drivers' criticism
-
Singer D4vd charged with murder over teen's body found in Tesla
-
UK PM denies misleading MPs, says officials hid Mandelson info
-
Tit-for-tat blockades once again cripple traffic in Hormuz
-
Cafu says 2026 World Cup is perfect time for Brazil to win again
-
Erdogan vows new measures after deadly Turkey school shootings
-
Rose to take charge at Bournemouth after Iraola exit
-
Olympic status a massive 'boost' for squash says European champion Crouin
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
A.Kunz--VB